ZYME Projected Dividend Yield
Zymeworks Inc ( NASDAQ : ZYME )Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. 20 YEAR PERFORMANCE RESULTS |
ZYME Dividend History Detail ZYME Dividend News ZYME Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |